Vectura Group PLC  

(Public, LON:VEC)   Watch this stock  
Find more results for VEC
+0.30 (0.17%)
Jul 3 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 177.50 - 180.60
52 week 113.25 - 183.75
Open 180.00
Vol / Avg. 551,334.00/706,247.00
Mkt cap 726.80M*
P/E 219.44
Div/yield     -
EPS 0.01*
Shares 406.20M
Beta     -
Inst. own     -
Jun 24, 2015
Vectura Group PLC at ROTH Healthcare Day - London
Jun 2, 2015
Vectura Group PLC at Jefferies Global Healthcare Conference

Key stats and ratios

Q1 (Mar '15) 2015
Net profit margin 21.24% 6.38%
Operating margin 0.26% -12.07%
EBITD margin - 26.03%
Return on average assets 5.61% 1.23%
Return on average equity 7.43% 1.65%
Employees 243 -
CDP Score - 74 C


One Prospect West
United Kingdom - Map
+44-1249-667700 (Phone)
+44-1249-667701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Vectura Group plc is a respiratory product development company. The Company focuses on the development of pharmaceutical therapies for treating airways-related diseases. The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, some of which are licensed to pharmaceutical companies. The Company’s product portfolio includes Adept, a 4% icodextrin solution used in surgery to reduce post-surgical adhesions; Advate used to treat haemophilia A; Asmasal used for rapid relief of asthma symptoms; Extraneal, a peritoneal dialysis solution containing icodextrin; Asmabec used as preventative therapy for asthma; Seebri Breezhaler, a muscarinic antagonist; Ultibro Breezhaler, a dual bronchodilator, and AirfluSal Forspiro, an inhaled combination therapy (salmeterol/fluticasone) for asthma and COPD. The Company’s pipeline products include VR588, VR611, VR942, VR475, VR465, VR647, VR179, VR736, SB010, NVA237, QVA149, VR876, VR315, VR506, and VR632.

Officers and directors

Trevor Michael Phillips Ph.D. Chief Operating Officer, President - US Operations, Director
Age: 53
Christopher Paul Blackwell Ph.D. Chief Executive, Executive Director
Age: 52
Andrew J. Oakley Group Chief Financial Officer, Executive Director, Company Secretary
Age: 52
Gerard Scheuch Chief Scientific Officer
Age: 58
Roger Heerman Chief Commercial Officer
Age: 41
Karl D. Keegan Ph.D. Chief Corporate Development Officer
Age: 48
Bruno F. J. Angelici Non-Executive Chairman of the Board
Age: 68
Per-Olof Andersson Non-Executive Director
John Robert Brown Ph.D., CBE Senior Independent Non-Executive Director
Age: 59
Susan Elizabeth Foden Ph.D. Non-Executive Independent Director
Age: 61